New analyses convince IQWiG that Novartis's MS drug is better than previously thought
This article was originally published in Scrip
Executive Summary
Germany's IQWiG has taken a fresh look at old data from Novartis's Gilenya (fingolimod) and decided that it is better than it previously thought at treating patients with multiple sclerosis.